JP2013525305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525305A5 JP2013525305A5 JP2013505156A JP2013505156A JP2013525305A5 JP 2013525305 A5 JP2013525305 A5 JP 2013525305A5 JP 2013505156 A JP2013505156 A JP 2013505156A JP 2013505156 A JP2013505156 A JP 2013505156A JP 2013525305 A5 JP2013525305 A5 JP 2013525305A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- multimeric ligand
- subject
- region
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 claims description 254
- 102000037865 fusion proteins Human genes 0.000 claims description 132
- 108020001507 fusion proteins Proteins 0.000 claims description 132
- 101150013553 CD40 gene Proteins 0.000 claims description 110
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 110
- 239000002773 nucleotide Substances 0.000 claims description 110
- 125000003729 nucleotide group Chemical group 0.000 claims description 110
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 107
- 206010060862 Prostate cancer Diseases 0.000 claims description 106
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 100
- 102000036639 antigens Human genes 0.000 claims description 92
- 108091007433 antigens Proteins 0.000 claims description 92
- 239000000427 antigen Substances 0.000 claims description 89
- 108091033319 polynucleotide Proteins 0.000 claims description 61
- 102000040430 polynucleotide Human genes 0.000 claims description 61
- 239000002157 polynucleotide Substances 0.000 claims description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 239000012528 membrane Substances 0.000 claims description 58
- 229920001184 polypeptide Polymers 0.000 claims description 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 58
- 230000008685 targeting Effects 0.000 claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims description 57
- 230000001086 cytosolic effect Effects 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 39
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 35
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 35
- 230000005747 tumor angiogenesis Effects 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 27
- 239000002246 antineoplastic agent Substances 0.000 claims description 25
- 229940127089 cytotoxic agent Drugs 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 230000028993 immune response Effects 0.000 claims description 17
- 238000002512 chemotherapy Methods 0.000 claims description 12
- 230000035945 sensitivity Effects 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 7
- 210000002307 prostate Anatomy 0.000 claims description 7
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 6
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 210000001165 lymph node Anatomy 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 102000001493 Cyclophilins Human genes 0.000 claims description 2
- 108010068682 Cyclophilins Proteins 0.000 claims description 2
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims description 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims description 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 2
- 229960001573 cabazitaxel Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims 11
- 229940127555 combination product Drugs 0.000 claims 11
- 241000701161 unidentified adenovirus Species 0.000 claims 6
- 230000035572 chemosensitivity Effects 0.000 claims 3
- 238000000034 method Methods 0.000 description 142
- 230000004614 tumor growth Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32512710P | 2010-04-16 | 2010-04-16 | |
| US61/325,127 | 2010-04-16 | ||
| US35176010P | 2010-06-04 | 2010-06-04 | |
| US61/351,760 | 2010-06-04 | ||
| US201161442582P | 2011-02-14 | 2011-02-14 | |
| US61/442,582 | 2011-02-14 | ||
| PCT/US2011/032572 WO2011130566A2 (en) | 2010-04-16 | 2011-04-14 | Method for treating solid tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016060361A Division JP2016117770A (ja) | 2010-04-16 | 2016-03-24 | 固形腫瘍を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525305A JP2013525305A (ja) | 2013-06-20 |
| JP2013525305A5 true JP2013525305A5 (enExample) | 2014-05-01 |
| JP5975983B2 JP5975983B2 (ja) | 2016-08-23 |
Family
ID=44799326
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505156A Active JP5975983B2 (ja) | 2010-04-16 | 2011-04-14 | 固形腫瘍を処置するための方法 |
| JP2016060361A Withdrawn JP2016117770A (ja) | 2010-04-16 | 2016-03-24 | 固形腫瘍を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016060361A Withdrawn JP2016117770A (ja) | 2010-04-16 | 2016-03-24 | 固形腫瘍を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110287038A1 (enExample) |
| EP (1) | EP2558109A4 (enExample) |
| JP (2) | JP5975983B2 (enExample) |
| AU (1) | AU2011239569B2 (enExample) |
| CA (1) | CA2795947A1 (enExample) |
| WO (1) | WO2011130566A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2557164A1 (en) * | 2003-02-18 | 2013-02-13 | Kevin M. Slawin | Induced activation in dendritic cells |
| EP2076272B1 (en) * | 2006-10-19 | 2015-07-29 | Baylor College Of Medicine | Generating an immune response by inducing cd40 and pattern recognition receptors |
| DK2331680T3 (en) * | 2008-09-22 | 2017-08-21 | Baylor College Medicine | Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters |
| JP5566466B2 (ja) | 2009-10-29 | 2014-08-06 | アバンテイス・フアルマ・エス・アー | カバジタキセルの新規の抗腫瘍的使用 |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| EP2786151B1 (en) * | 2011-11-29 | 2019-07-03 | F.Hoffmann-La Roche Ag | Methods for prostate cancer analysis |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| KR20150131218A (ko) | 2013-03-14 | 2015-11-24 | 벨리쿰 파마슈티컬스, 인크. | T 세포 증식의 제어 방법 |
| KR20150130284A (ko) * | 2013-03-15 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 백신 및 이를 이용한 치료 방법 |
| AU2014228838B2 (en) | 2013-03-15 | 2017-02-02 | The Trustees Of The University Of Pennsylvania | Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same |
| CN105518018B (zh) | 2013-03-15 | 2020-04-03 | 细胞基因公司 | 修饰的t淋巴细胞 |
| CA2912172A1 (en) | 2013-06-05 | 2014-12-11 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| JP6496472B2 (ja) * | 2013-07-03 | 2019-04-03 | 三菱重工機械システム株式会社 | 車載器、及びスプーフィング検知方法 |
| CN106132423B (zh) * | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| EP2940136A1 (en) * | 2014-04-30 | 2015-11-04 | QIAGEN GmbH | Method for isolating poly(A) nucleic acids |
| JP6868554B2 (ja) | 2014-09-02 | 2021-05-12 | ベリカム ファーマシューティカルズ， インコーポレイテッド | ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激 |
| AU2015341481C1 (en) | 2014-11-03 | 2021-09-16 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T cell receptors directed against Bob1 and uses thereof |
| US10975137B2 (en) * | 2014-11-06 | 2021-04-13 | University Of Maryland, Baltimore | CD8a and t cell receptor variants and methods of using same in modulating immune cell responses |
| EP3608408A1 (en) * | 2014-12-15 | 2020-02-12 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| WO2017015553A1 (en) * | 2015-07-22 | 2017-01-26 | University Of Washington | Compositions and methods for producing pro-inflammatory macrophages |
| KR102697827B1 (ko) | 2015-07-28 | 2024-08-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도 |
| AU2016343845B2 (en) * | 2015-10-30 | 2023-04-13 | Baylor College Of Medicine | Compositions and methods for the treatment of HER2-expressing solid tumors |
| JP6904667B2 (ja) | 2016-06-14 | 2021-07-21 | 日本光電工業株式会社 | バイトブロック及びガスセンサキット |
| WO2018077385A1 (en) * | 2016-10-25 | 2018-05-03 | Biontech Rna Pharmaceuticals Gmbh | Dose determination for immunotherapeutic agents |
| US20210147507A1 (en) | 2017-05-09 | 2021-05-20 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
| WO2019045791A1 (en) * | 2017-08-28 | 2019-03-07 | Board Of Trustees Of Michigan State University | COMPOSITIONS AND METHODS FOR TREATING CANCER AND INFECTIONS USING BACTERIOPHAGE AND ITS MUTANTS |
| JP2021500861A (ja) * | 2017-09-27 | 2021-01-14 | ユニバーシティ オブ サザン カリフォルニア | 共刺激のための新規のプラットフォーム、新規のｃａｒ設計、および養子細胞療法のための他の増強 |
| EP3720479A2 (en) | 2017-12-08 | 2020-10-14 | Bellicum Pharmaceuticals, Inc. | Methods for enhancing and maintaining car-t cell efficacy |
| EP3728189A1 (en) | 2017-12-20 | 2020-10-28 | Bellicum Pharmaceuticals, Inc. | Multimeric piperidine derivatives |
| US20220000921A1 (en) * | 2018-11-20 | 2022-01-06 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified Cell Expressing Therapeutic Agent and Uses thereof |
| KR20220097875A (ko) | 2019-09-03 | 2022-07-08 | 마이얼로이드 테라퓨틱스, 인크. | 게놈 통합을 위한 방법 및 조성물 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CA3161488A1 (en) * | 2019-12-11 | 2021-06-17 | Daniel Getts | Therapeutic cell compositions and methods for manufacture and uses thereof |
| WO2021142305A2 (en) * | 2020-01-10 | 2021-07-15 | Coimmune, Inc. | Methods of treating tumors |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| EP4161536A4 (en) | 2020-06-04 | 2024-08-14 | Carisma Therapeutics Inc. | Novel constructs for chimeric antigen receptors |
| CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
| MX2023005201A (es) | 2020-11-04 | 2023-06-28 | Myeloid Therapeutics Inc | Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas. |
| BR112023018832A2 (pt) | 2021-03-17 | 2023-12-26 | Myeloid Therapeutics Inc | Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas |
| EP4337268A4 (en) | 2021-05-11 | 2025-06-04 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215472A1 (en) * | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| EP2557164A1 (en) * | 2003-02-18 | 2013-02-13 | Kevin M. Slawin | Induced activation in dendritic cells |
| JP2007511507A (ja) * | 2003-11-14 | 2007-05-10 | ジェンベク、インコーポレイティッド | 癌を処置するための治療レジメン |
| EP2076272B1 (en) * | 2006-10-19 | 2015-07-29 | Baylor College Of Medicine | Generating an immune response by inducing cd40 and pattern recognition receptors |
| BRPI0820270A2 (pt) * | 2007-11-07 | 2015-06-16 | Celldex Therapeutics Inc | Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular. |
| AU2009221915A1 (en) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 12 binding proteins |
| WO2009151503A2 (en) * | 2008-04-10 | 2009-12-17 | University Of Florida Research Foundation, Inc. | Compositions and methods for the treatment of a neoplasia |
| DK2331680T3 (en) * | 2008-09-22 | 2017-08-21 | Baylor College Medicine | Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters |
-
2011
- 2011-04-14 EP EP11769619.5A patent/EP2558109A4/en not_active Withdrawn
- 2011-04-14 JP JP2013505156A patent/JP5975983B2/ja active Active
- 2011-04-14 US US13/087,329 patent/US20110287038A1/en not_active Abandoned
- 2011-04-14 AU AU2011239569A patent/AU2011239569B2/en not_active Ceased
- 2011-04-14 CA CA2795947A patent/CA2795947A1/en not_active Abandoned
- 2011-04-14 WO PCT/US2011/032572 patent/WO2011130566A2/en not_active Ceased
-
2013
- 2013-03-06 US US13/786,652 patent/US20140023647A1/en not_active Abandoned
-
2016
- 2016-03-24 JP JP2016060361A patent/JP2016117770A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525305A5 (enExample) | ||
| Alnefaie et al. | Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions | |
| Luo et al. | Progress and prospect of immunotherapy for triple-negative breast cancer | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| CN112055695A (zh) | 用于基因表达的纳米粒子和其用途 | |
| Brunell et al. | Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities | |
| CN115297868B (zh) | 用于编码核糖核酸的器官保护性表达和调节的组合物及方法 | |
| WO2017075465A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 | |
| US11788093B2 (en) | Chimeric antigen receptor t-cells expressing interleukin-8 receptor | |
| KR102741572B1 (ko) | 조직에서 코딩 리보핵산의 표적화된 전달, 발현 및 조절을 위한 조성물 및 방법 | |
| Yang et al. | Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells | |
| CN114786686A (zh) | Gold控制的转基因的联合疗法 | |
| Lee et al. | Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models | |
| Wang et al. | Different evasion strategies in multiple myeloma | |
| Walters et al. | Modulating expression of inhibitory and stimulatory immune ‘checkpoints’ using nanoparticulate-assisted nucleic acid delivery | |
| KR20220092543A (ko) | 암의 치료를 위한 의약, 조합 의약, 의약 조성물, 면역 응답성 세포, 핵산 전달 비히클 및 제품 | |
| Snyder et al. | Good CARMA: Turning bad tumor‐resident myeloid cells good with chimeric antigen receptor macrophages | |
| Chekaoui et al. | Cancer vaccines: an update on recent achievements and prospects for cancer therapy | |
| Younis et al. | Understanding gene involvement in hepatocellular carcinoma: implications for gene therapy and personalized medicine | |
| Carreira et al. | Nanomedicines as multifunctional modulators of melanoma immune microenvironment | |
| US20240218019A1 (en) | Methods and compositions comprising mhc class i peptides | |
| CN113929767A (zh) | 具有高亲和力的t细胞受体及其用途 | |
| Mokhtari et al. | The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers. 2021; 13: 3596 | |
| Yuan et al. | CD8+ T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA | |
| US20220372170A1 (en) | Macrophage CAR (MOTO-CAR) In Immunotherapy |